TNNI3 and hyperlipidemia: A comprehensive model that combined baseline clinical risk factors (age, hyperlipidemia, anthracycline/radiotherapy use) with on-treatment changes in LVGLS, LVEF, and hs-cTnI demonstrated excellent discriminatory power, with an AUC of 0.88 (95% CI 0.85-0.91).